Pricing
  1. JP-listed companies
  3. Financials
  4. Gross margin (%)

(4586)

Market cap
¥6.6B
P/E ratio
Medrex develops new pharmaceuticals using proprietary skin-patch delivery technology that improves drug effectiveness and reduces side effects.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndGross margin (%) YoY (%)
Dec 31, 202599.1-0.82%
Dec 31, 202499.9+8.72%
Dec 31, 202391.9-3.89%
Dec 31, 202295.6+31.16%
Dec 31, 202172.9-24.55%
Dec 31, 202096.6-0.32%
Dec 31, 201996.9+36.69%
Dec 31, 201870.9-26.50%
Dec 31, 201796.4+46.01%
Dec 31, 201666.1-2.50%
Dec 31, 201567.8+5.01%
Dec 31, 201464.5

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat